Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis.

Colorectal cancer. Nat Rev Dis Prim (2015) 1.07

Ulcerative colitis-associated colorectal cancer. World J Gastroenterol (2014) 0.97

The new deal: a potential role for secreted vesicles in innate immunity and tumor progression. Front Immunol (2015) 0.93

Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open (2015) 0.91

Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr (2015) 0.83

Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line. Cancer Sci (2015) 0.78

The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut (2016) 0.78

Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies. World J Gastrointest Pharmacol Ther (2016) 0.78

Colorectal Cancer in Inflammatory Bowel Disease: Epidemiology, Pathogenesis and Surveillance. Gastrointest Tumors (2014) 0.76

Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. Int J Colorectal Dis (2016) 0.76

KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. Oncotarget (2017) 0.75

Use of Cancer Stem Cells to Investigate the Pathogenesis of Colitis-associated Cancer. Inflamm Bowel Dis (2016) 0.75

Letter: low risk of colorectal cancer in a Greek cohort of inflammatory bowel disease patients. Aliment Pharmacol Ther (2014) 0.75

Chromoendoscopy Is Better: So Why Am I Not (yet) Using it for Routine Inflammatory Bowel Disease Surveillance? Clin Gastroenterol Hepatol (2015) 0.75

The Changing Phenotype of Inflammatory Bowel Disease. Gastroenterol Res Pract (2016) 0.75

Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis. BMC Surg (2017) 0.75

Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. World J Gastroenterol (2016) 0.75

Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes. Medicine (Baltimore) (2016) 0.75

Ulcerative colitis with inflammatory polyposis in a teenage boy: a case report. World J Gastroenterol (2015) 0.75

Clonal evolution of colorectal cancer in IBD. Nat Rev Gastroenterol Hepatol (2017) 0.75

Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc (2016) 0.75

Prognosis of Colorectal Cancer in Inflammatory Bowel Disease: Data from a State Registry. Dig Dis Sci (2017) 0.75

[Influence of therapy on risk of cancer in rheumatoid arthritis : Pathophysiological principles]. Z Rheumatol (2016) 0.75

Daily Intake of High-Fat Diet with Lysophosphatidic Acid-Rich Soybean Phospholipids Augments Colon Tumorigenesis in Kyoto Apc Delta Rats. Dig Dis Sci (2017) 0.75

Dicer suppresses cytoskeleton remodeling and tumorigenesis of colorectal epithelium by miR-324-5p mediated suppression of HMGXB3 and WASF-2. Oncotarget (2017) 0.75

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther (2015) 3.52

Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther (2011) 3.16

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut (2010) 2.98

Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther (2010) 2.51

Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol (2012) 2.47

Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther (2015) 2.00

Systematic review: hepatitis-associated aplastic anaemia--a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther (2009) 1.83

Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther (2006) 1.74

Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol (2005) 1.67

Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther (2011) 1.63

13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease. Dig Liver Dis (2000) 1.51

Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther (2011) 1.50

Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2012) 1.50

Prevalence of Helicobacter pylori infection in medical professionals in Spain. Eur J Gastroenterol Hepatol (1999) 1.42

Epidemiology of inflammatory bowel disease in Spain. A systematic review. Rev Esp Enferm Dig (2001) 1.39

Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. Inflamm Bowel Dis (2007) 1.39

Commentary: comparators in H. pylori eradication--stating the ethics of statins. Aliment Pharmacol Ther (2012) 1.38

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.36

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther (2005) 1.34

Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther (2014) 1.22

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2011) 1.15

The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther (2011) 1.15

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther (2010) 1.14

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 1.14

Epinephrine injection versus epinephrine injection and a second endoscopic method in high risk bleeding ulcers. Cochrane Database Syst Rev (2007) 1.14

Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. Antimicrob Agents Chemother (1999) 1.11

Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease. Aliment Pharmacol Ther (2014) 1.08

Letter: the irony of oral iron - not an underdog for post-gastrointestinal bleeding anaemia. Aliment Pharmacol Ther (2014) 1.08

Letter: acute severe ulcerative colitis - should all patients be treated equally? Aliment Pharmacol Ther (2014) 1.08

Letter: distinguishing PPI-responsive oesophageal eosinophilia from eosinophilic oesophagitis - still a long way to go. Aliment Pharmacol Ther (2014) 1.08

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther (2003) 1.08

Meta-analysis: predictors of rebleeding after endoscopic treatment for bleeding peptic ulcer. Aliment Pharmacol Ther (2011) 1.07

Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther (2011) 1.07

Letter: Persisting clinical symptoms in microscopic colitis in remission. Aliment Pharmacol Ther (2014) 1.07

Letter: mucosal healing in ulcerative colitis--higher relevance than in Crohn's disease? Aliment Pharmacol Ther (2013) 1.07

Letter: infliximab in severe ulcerative colitis - is it useful for all patients? Aliment Pharmacol Ther (2013) 1.07

Usefulness of manometry to select patients with anal fissure for controlled anal dilatation. Rev Esp Enferm Dig (2010) 1.07

Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided. Aliment Pharmacol Ther (2013) 1.06

Letter: PPI-responsive oesophageal eosinophilia--from initial scepticism to consistent prospective data. Aliment Pharmacol Ther (2014) 1.06

Commentary: overcoming antibiotic resistance with Helicobacter pylori therapy--optimisation is the way forward. Aliment Pharmacol Ther (2013) 1.06

Letter: should colectomy be the end-point to evaluate the effectiveness of drug therapies in severe ulcerative colitis? Aliment Pharmacol Ther (2013) 1.06

Letter: Bismuth quadruple therapy with Pylera for H. pylori infection. Aliment Pharmacol Ther (2014) 1.05

Letter: psychological remission - a future endpoint in inflammatory bowel disease? Aliment Pharmacol Ther (2014) 1.05

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther (2012) 1.05

Letter: predictors of severe disease in ulcerative colitis - the same or different in Crohn's disease? Aliment Pharmacol Ther (2014) 1.04

Collagenous colitis in Spain: a report of nine new cases. Rev Esp Enferm Dig (1999) 1.00

Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther (2008) 0.99

Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther (2012) 0.99

The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther (2013) 0.97

Letter: Recommendations for the management of latent tuberculosis infection in IBD patients may not be applicable in all settings. Aliment Pharmacol Ther (2013) 0.96

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther (2002) 0.96

Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2008) 0.95

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther (2001) 0.94

Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. Scand J Gastroenterol (1997) 0.91

[Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic review]. Rev Esp Enferm Dig (2007) 0.89

Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther (2003) 0.89

Angiogenesis in inflammatory bowel disease. Eur J Clin Invest (2008) 0.89

Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther (2007) 0.89

Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther (2013) 0.89

Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol (2012) 0.89

[Endoscopic choledochoduodenostomy in the treatment of impacted calculi in Vater's papilla]. Rev Esp Enferm Dig (1991) 0.87

[Anemia and inflammatory bowel disease]. Rev Esp Enferm Dig (2008) 0.85

The colorectal carcinoma prognosis factors. Significance of diagnosis delay. Rev Esp Enferm Dig (2006) 0.85

Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Aliment Pharmacol Ther (2013) 0.85

Concordance between noninvasive tests in detecting Helicobacter pylori and potential use of serology for monitoring eradication in gastric ulcer. J Clin Gastroenterol (2000) 0.84

Factors involved in the pathogenesis of Helicobacter pylori infection. Rev Esp Enferm Dig (2006) 0.83

Impact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression: a multinational primary care study. Aliment Pharmacol Ther (2013) 0.83

Prevalence of macrocreatinkinase type 1 in patients with inflammatory bowel disease. Dig Dis Sci (2007) 0.82

Intensification of infliximab therapy in Crohn's disease: efficacy and safety. J Crohns Colitis (2011) 0.82

Usefulness of the combined IgG and IgA antibody determinations for serodiagnosis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol (1997) 0.82

High seroprevalence of Helicobacter pylori infection in coronary heart disease. Lancet (1995) 0.81

High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther (2012) 0.81

Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis (2011) 0.81

[Helicobacter pylori infection: antibiotic resistance]. Rev Esp Enferm Dig (2007) 0.81

Spanish scientific output on Helicobacter pylori. A study through Medline. Rev Esp Enferm Dig (2006) 0.80

Helicobacter pylori infection and precancerous lesions of the stomach. Hepatogastroenterology (2002) 0.80

[Is there any association between Helicobacter pylori infection and peptic esophagitis?]. Med Clin (Barc) (1995) 0.80

Predictors of response to infliximab in patients with fistulizing Crohn's disease. Rev Esp Enferm Dig (2004) 0.79

Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther (2012) 0.79

Health care costs of complex perianal fistula in Crohn's disease. Dig Dis Sci (2013) 0.79

[Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease]. Gastroenterol Hepatol (2010) 0.78

Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. Rev Esp Enferm Dig (2005) 0.78

[The importance of obtaining biopsies of the gastric body in the follow-up after eradicating treatment of Helicobacter pylori]. Med Clin (Barc) (1995) 0.78

Letter: measurement of anti-TNF-α levels and antibodies against the drug. Aliment Pharmacol Ther (2013) 0.78

Helicobacter pylori: its discovery and relevance for medicine. Rev Esp Enferm Dig (2006) 0.78

Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther (2007) 0.78

Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. Eur J Med Chem (2013) 0.78

Absence of isochromosome 12p in a pineal region malignant germ cell tumor. Cancer Genet Cytogenet (1990) 0.77

Helicobacter pylori infection and gastric mucosal epithelial cell apoptosis. Rev Esp Enferm Dig (2005) 0.77

ABO blood groups, rhesus factor and Helicobacter pylori. Rev Esp Enferm Dig (1998) 0.77

[Basal concentrations of gastrin and pepsinogen I and II in gastric ulcer: influence of Helicobacter pylori infection and usefulness in the control of the eradication]. Gastroenterol Hepatol (2001) 0.77

[The attitude in a failure to eradicate Helicobacter pylori: surrender or fight?]. Med Clin (Barc) (1998) 0.77

Congenital subependymal giant-cell astrocytoma: case report with prenatal ultrasonogram. Pediatr Radiol (1999) 0.77

Geographic differences and the role of cagA gene in gastroduodenal diseases associated with Helicobacter pylori infection. Rev Esp Enferm Dig (2001) 0.77

[Antibodies against Helicobacter pylori in saliva. Study of their validity versus breath test and its agreement with serology]. Aten Primaria (2000) 0.76